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A B S T R A C T
Polyphenols synthesized by plants and fungi have various pharmacological eﬀects. The ability of polyphenols to
modulate sirtuins has gained considerable interest due to the role of sirtuins in aging, insulin sensitivity, lipid
metabolism, inﬂammation, and cancer. In particular, sirtuin 6 (SIRT6) has gained importance in regulating a
variety of cellular processes, including genomic stability and glucose metabolism. On the other hand, quercetin
has been demonstrated to modulate sirtuins and to protect against several chronic diseases. In this study, two
quercetin derivatives, diquercetin and 2-chloro-1,4-naphtoquinone-quercetin, were identiﬁed as promising
SIRT6 inhibitors with IC50 values of 130 μM and 55 μM, respectively. 2-Chloro-1,4-naphtoquinone-quercetin also
showed potent inhibition against SIRT2, with an IC50 value of 14 μM. Diquercetin increased the Km value of
NAD+, whereas 2-chloro-1,4-naphthoquinone-quercetin increased the Km value of the acetylated substrate.
Molecular docking studies suggest that diquercetin prefers the binding site of the nicotinamide (NAM) moiety,
whereas 2-chloro-1,4-naphtoquinone-quercetin prefers to dock into the substrate binding site. Overall, the re-
sults of in vitro studies and molecular modeling indicate that diquercetin competes with nicotinamide adenine
dinucleotide (NAD+), whereas 2-chloro-1,4-naphthoquinone-quercetin competes with the acetylated substrate
in the catalytic site of SIRT6. Natural polyphenolic compounds targeting sirtuins show promise as a new ap-
proach in the search for novel and eﬀective treatments for age-related diseases.
1. Introduction
Sirtuins (SIRTs) are NAD+-dependent protein deacetylases that
have emerged as exciting targets for several diseases. There are seven
SIRTs in mammals that diﬀer in cellular sublocation: SIRT1, SIRT6, and
SIRT7 are nuclear enzymes, SIRT2 is primarily cytosolic, and SIRT3,
SIRT4, and SIRT5 are found in mitochondria. The regulation of SIRTs
has been studied over the past 15 years and has led to the identiﬁcation
of many SIRT inhibitors and activators. Most of these compounds target
SIRT1, but more regulators have recently been identiﬁed for other
SIRTs.
SIRT6 plays an important role in DNA damage signaling and repair
and is involved in metabolism; therefore, it is a potential therapeutic
target in the context of neurodegenerative diseases, metabolic disorders
including diabetes, and cancer [1–3]. Several studies indicate that
SIRT6 levels are reduced in some types of cancers and that SIRT6 de-
ﬁciency results in genetic instability and tumorigenesis [4,5]. However,
some reports have shown that SIRT6 may play an opposite role and act
as a tumor promoter. For example, SIRT6 is upregulated in some can-
cers, such as hepatocellular carcinoma and multiple myeloma, and the
overexpression of SIRT6 is associated with poor prognosis [6]. SIRT6
also inﬂuences metabolic pathways, such as glycolysis and gluconeo-
genesis, which may aﬀect tumor growth. Taken together, these ﬁndings
indicate that SIRT6 function is associated with multiple key pathways
related to aging. However, the medical and therapeutic relevance of
SIRT6 in humans remains incompletely understood.
Black mulberry (Morus nigra) is rich in polyphenols and alkaloids,
which have hypoglycemic, hypolipidemic, hypotensive, anti-
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inﬂammatory, and anti-tumor eﬀects [7–9]. Quercetin is one of the
most studied polyphenols and it has many health beneﬁts. However, its
low bioavailability prevents clinical use and thus there is need for de-
veloping derivatives with better pharmaceutical properties. Novel
quercetin derivatives, mainly with pivaloyl-, acetyl-, feruloyl-, and
caﬀeoyl-groups, have been previously designed, synthesized, and
characterized with respect to antioxidant/pro-oxidant, cytotoxic, anti-
tumor, and anti-inﬂammatory properties [10,11]. The quercetin deri-
vatives that have an inhibitory eﬀect on aldose reductase and alpha-
glucosidase may be promising in the treatment of diabetic disorders
[12,13]. Interestingly, quercetin has been shown both in vitro and in
vivo SIRT1 activation either directly or indirectly [14,15]. Quercetin
together with resveratrol upregulates SIRT1 and SIRT2 expression in
vivo [16]. The role of quercetin is not restricted to SIRT1. We have
previously shown that polyphenols like kaempferol and quercetin ex-
ceed 40% SIRT6 inhibition at 10 μM and 100 μM concentrations, re-
spectively [17].
Novel quercetin derivatives, mainly pivalate or halogen-bearing
compounds, have also been shown to induce a signiﬁcant concentra-
tion-dependent decrease in sarcoplasmic reticulum Ca2+-adenosine
triphosphate (ATP)ase (SERCA) activity. SERCA maintains Ca2+
homeostasis, and alteration in its expression and activity can result in
myopathy, heart failure, diabetes, or cellular malignancy. The antic-
ancer properties of ﬂavonoids may be mediated by their ability to in-
duce apoptosis via the Ca2+-dependent mitochondrial pathway [18]
and by inhibiting SERCA [19]. On the other hand, some quercetin de-
rivatives stimulate SERCA activity. Modulation of SERCA by poly-
phenols may represent an approach to the therapy of diseases involving
SERCA impairment [20]. One example of such diseases is diabetes, in
which there are disruptions in Ca2+ homeostasis aﬀects pancreatic in-
sulin and glucagon secretion. Interestingly, SIRT6 is also linked to
maintaining Ca2+ homeostasis as it regulates the production of Ca2+-
mobilizing nucleotides [21].
The aim of this study was to identify novel types of scaﬀolds for
designing potent SIRT6 inhibitors because there are still a limited
number of SIRT6 inhibitors. We explored how a set of quercetin and
rutin derivatives, along with other polyphenols isolated from the root
bark of Morus nigra, aﬀect SIRT6 deacetylation activity. Previously
these compounds were shown to have the ability to modulate SERCA
activity and have promising cytotoxic, anti-cancerous, and anti-in-
ﬂammatory properties [22–25]. We observed that the most potent in-
hibitors of SIRT6 were diquercetin (compound 25) and 2-chloro-1,4-
naphtoquinone-quercetin (compound 3). We also studied the possible
binding poses and interactions of these inhibitors with molecular
docking. Interestingly, they also showed inhibition towards other sir-
tuins.
2. Materials and methods
2.1. Polyphenols
Kaempferol, quercetin and rutin (compound 11) were ordered from
Sigma Aldrich (USA). Quercetin derivatives (compounds 2, 3, 7, 8, and
20–25) were synthesized as described previously by Veverka et al. [10],
and compound 12 was synthesized according to Raza et al. [26]. Rutin
derivatives were prepared via lipase-catalyzed esteriﬁcation of rutin
with palmitic (compound 18), stearic (compound 19), or arachidonic
acid (compound 14) in 2-methylbutan-2-ol at 60 °C as previously pub-
lished [27]. Pycnogenol (compound 13) is from Horphag Research Ltd.
(UK). Polyphenolic compounds from the root bark of Morus nigra were
isolated in pure form and identiﬁed by high-resolution mass spectro-
metry (HRMS) and 2D nuclear magnetic resonance (NMR) techniques:
morusin (compound 4) according to Kim et al. [28]; kuwanon E
(compound 5) and kuwanon U (compound 6) according to Jeong et al.
[29]; moracin P (compound 9) as described by Lee et al. [30]; and
moracin R (compound 10) as described by Kapche et al. [31].
Benzothiophene derivatives (compounds 15, 16, 17) were synthetized
according to Algso et al. [32,33].
2.2. Materials
7-Amino-4-methylcoumarin (AMC) labelled substrate, Ac-RYQK
(Ac)-AMC, was purchased from CASLO ApS (Denmark). NAD+ was
from Sigma Aldrich (USA). Enhanced chemiluminescence (ECL) prime
western blotting detection reagents were from Amersham BioSciences
(UK). Novex 10–20% gradient gels and anti-rabbit-IgG (mouse)
Horseradish peroxidase (HRP)-conjugated secondary antibody
(G21234) were from Life Technologies (UK). Rabbit anti-acetyl histone
3 lysine 9 (H3K9) antibody (06-942) and puriﬁed chicken core histones
(13–107) were from Millipore (USA). Rabbit anti-histone 3 (H3) anti-
body (9715S) was purchased from Cell Signaling Technology (USA).
Human SIRT6 expression vector hSIRT6-pGEX-6P3 was kindly
provided by Prof. Katrin Chua (Stanford, USA). Recombinant GST-
tagged SIRT6 was produced by fermentation in E. coli BL21(DE3)-
pRARE. The production was done at+ 16 °C with 0.1mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) for 20 h and the soluble over-
expressed protein was puriﬁed on glutathione agarose (Sigma, Saint
Louis, USA).
2.3. In vitro assays for SIRT6
2.3.1. SIRT6 screening
At ﬁrst a set of compounds together with positive controls kaemp-
ferol and quercetin, were screened against SIRT6 using deacetylation
assay as previously described [34]. Experiments were replicated three
times, except for compounds 12 and 14 that were measured two times,
and the data were expressed as mean ± standard deviation (SD).
Brieﬂy, compounds in dimethyl sulfoxide (DMSO) (200 μM), the ﬁnal
solvent concentrations in the samples did not exceed 3%, were in-
cubated for 90min with GST-SIRT6 (4.5 μg/well), Ac-RYQK(Ac)-AMC
(320 μM), and NAD+ in Tris Buﬀer [25mM, pH 8.0] at+ 37 °C. The
sample reactions were terminated by adding 50 μl of developer solution
(6 μg/μl trypsin and 40mM NAM) to all wells and followed by addition
of SIRT6 to the control wells. The plates were incubated for 30min at
room temperature and the ﬂuorescence was measured with excitation
and emission wavelengths of 380 and 440 nm, respectively, using En-
Vision 2104 Multilabel Reader (PerkinElmer, Finland).
2.3.1.1. Immunoblotting assay. Screening assay results of the most
potent compounds, as well as those of positive controls, kaempferol
and quercetin, were conﬁrmed using western blot analysis as previously
described [35]. Brieﬂy, 50 μM and 200 μM concentrations of
compounds and 2.5% DMSO control were incubated for 30min in the
presence of 3 μg of puriﬁed recombinant GST-SIRT6, 1.25 μg puriﬁed
chicken core histones, and 500 μM NAD+ in 25mM Tris-HCl, pH 8.0
at+ 37 °C. The reaction was stopped with Laemmli (sample buﬀer) and
proteins were separated by SDS-PAGE using 10–20% gradient gels and
transferred onto polyvinylidene diﬂuoride (PVDF) membranes. H3K9
acetylation was detected with rabbit anti-acetyl H3K9 antibody
(1:2000) followed by anti-rabbit HRP-conjugated secondary antibody
(1:10 000). Membranes were stripped and re-probed with rabbit anti-
histone H3 antibody (1:8000). Chemiluminescent signal detection and
image acquisition were carried out using ECL prime western blotting
detection reagents. Densitometric analysis of protein bands was carried
out using ImageJ 1.32 software and followed by statistical analysis
using Graph Pad Prism Software version 6 (California, USA).
2.3.2. Dose response and Lineweaver-Burk plots analysis
Dose responses of the most potent compounds (25 and 3) were
determined at a concentration range of 12 μM to 1000 μM as described
above (2.3.1) as means ± SD from triplicate determinations.
Percentages of remaining SIRT6 activity were plotted as a function of
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the logarithm of compounds’ (25 and 3) molarity, and the curves were
ﬁtted to a sigmoid dose-response equation using Graph Pad Prism
Software version 6 (California, USA). Lineweaver-Burk plots (Double-
reciprocal plots) assay was performed as described above (2.3.1) in the
presence or absence of compounds 25 or 3 (200 μM, ﬁnal concentra-
tion). Samples contained a constant concentration of NAD+ (3mM) or
peptide substrate (600 μM) with increasing concentrations of peptide
substrate (ranging from 100 μM to 1.2 mM) or NAD+ (ranging from 300
μM to 2.4mM). Lineweaver-Burk plots analyses were constructed as
means ± SD from three diﬀerent experiments using Graph Pad Prism
Software version 6 (California, USA).
2.4. In vitro studies for SIRT1–3
To investigate the activity of the most potent compounds (25 and 3)
towards other sirtuins, the deacetylaton activities of SIRT1–3 were
determined as previously described with a Fluor de Lys sirtuin assays
(n=3 ± SD). Since 200 μM concentration of compound 3 resulted in
robust inhibition of the other sirtuins, a lower concentration (50 μM)
was used to study variation between diﬀerent SIRTs. Since compounds
25 and 3 showed good inhibition towards SIRT2, lower concentration
of compounds (10 μM) were also examined, and known sirtuin in-
hibitors Ex-527 and Suramin was included as reference compounds.
Assays based on the method described in the BioMol product sheet
(Enzo Life Sciences, Ann Arbor, MI, USA). BioMol KI177 substrate for
SIRT1 and KI179 substrate for SIRT2 and SIRT3 were used. Brieﬂy, the
reaction was started by incubating the enzyme (SIRT1, SIRT2 or SIRT3)
with the reaction mixture containing acetylated peptide substrate (0.7
Km: 58 μM for SIRT1, 198 μM for SIRT2, and 32 μM for SIRT3), NAD+
(0.9 Km: 558 μM for SIRT1, 547 μM for SIRT2, and 2mM for SIRT3),
and 5% DMSO or compounds in 5% ﬁnal DMSO concentration.
Incubation was done at 37 °C, and lasted for 1 h. The developer and
nicotinamide (2mM in histone deacetylase (HDAC) assay buﬀer giving
total volume of 50 μl) were added and the incubation was continued for
45min at 37 °C. The ﬂuorescence was determined with excitation and
emission wavelengths of 355 nm and 460 nm respectively using a
Victor™ 1420 Multilabel Counter (PerkinElmer Inc., Waltham, MA,
USA). Alternatively, the ﬂuorescence was measured using EnVision
2104 Multilabel Reader (PerkinElmer, Waltham, MA, USA) with ex-
citation and emission wavelengths of 370 nm and 460 nm, respectively.
2.5. Molecular modeling methods
Schrödinger Maestro software version 11.4.011 (Small-Molecule
Drug Discovery Suite 2017-4) [36] was used in molecular modeling
studies. The most potent compounds, 25 and 3 were constructed and
prepared with LigPrep at pH 7.4 using standard settings. Protein
structures of SIRT6 (protein data bank (PDB) ID 3ZG6) [37] and SIRT2
(PDB ID: 4RMG) [38] were preprocessed with standard settings at pH
7.4 using protein Preparation Wizard. All possible isomers for com-
pound 25 were constructed due to the fact that a mixture of compound
25 isomers was applied in in vitro testing.
Two grids for SIRT6 were constructer. The center of the ﬁrst grid
was in the middle of residues Leu7, Pro9, Ala11, Gly50, Phe62, Phe84,
Ser86, and Asp114. This grid site is close to the NAM moiety binding
site of NAD+, which is a quite common inhibitor binding site among
other sirtuins. The center of the second grid was at substrate binding
site in the middle of the residues Val113, His131, and Leu184. The grid
center for SIRT2 was set to be in the middle of co-crystallized ligand,
sirtuin-rearranging ligand2 (SirReal2). Compounds were docked with
InducedFit Docking and with standard settings.
3. Results
3.1. In vitro studies for SIRT6
A set of polyphenols (see Supplementary Table S1) was investigated
for SIRT6 inhibition using a ﬂuorogenic-based deacetylation assay at a
concentration of 200 μM (Fig. 1). Known SIRT6 inhibitors, kaempferol
and quercetin, were used as reference compounds and showed 38% and
68% inhibition of SIRT6, respectively. We were interested in de-
termining those compounds that exceeded 50% inhibition of SIRT6.
Interestingly, the most potent inhibitors were diquercetin (com-
pound 25) and 2-chloro-1,4-naphtoquinone-quercetin (compound 3),
which exceeded 80% inhibition. In contrast, the combination of three
quercetin molecules bound with Fe-salt (compound 12) had an inhibi-
tion potency below 40%. Compound 2 showed 60% inhibition, whereas
the rest of the quercetin derivatives were weak inhibitors. Rutin
(compound 11) showed inhibition of 60%, but rutin derivatives ex-
hibited only 40% inhibition.
The inhibitory eﬀect against SIRT6 deacetylation activity of the
known SIRT6 modulators and the most potent compounds of this study
were conﬁrmed using in vitro immunoblotting assay with core histone
protein 3 as a substrate (Fig. 2, Supplementary Fig. S1). The core his-
tone consisted of H2A, H2B, H3, and H4 proteins. The remaining levels
of H3 acetylation on lysine 9 were determined to evaluate inhibition of
compounds. H3K9Ac levels were normalized relative to H3, and
quantiﬁcation was presented as fold of change with respect to the
control. The results with core histone show that kaempferol stimulated
SIRT6 deacetylation activity at a concentration of 200 μM. In contrast,
quercetin decreased activity at both concentrations although not sig-
niﬁcantly. Like the results using a ﬂuorogenic-based assay, the core
histone studies showed that compounds 25 and 3 inhibited SIRT6 at a
concentration of 200 μM.
We also performed a dose-response study for the most potent
compounds, compounds 25 and 3, which displayed IC50 values of 130
μM and 55 μM, respectively (Fig. 3A). There was no obvious variation
in the inhibitory activity of compound 25 with diﬀerent peptide sub-
strate concentrations, suggesting that compound 25 is not a substrate
competitive inhibitor (Fig. 3B). In contrast, compound 25 demonstrated
diﬀerences in inhibition with varying NAD+ cofactor concentrations
and, as a result, an increased Km value indicating cofactor competitive
inhibition (Fig. 3C). Interestingly, compound 3 increased the Km value
of substrate and inhibited SIRT6 in a competitive manner (Fig. 3B),
whereas no competition against NAD+ cofactor was observed (Fig. 3C).
Fig. 1. Compounds 25, 2, 3, and 11 showed over 50% inhibition towards SIRT6
at 200 μM concentration. Light grey bars represent inhibition of reference
compounds, kaempferol and quercetin. The data are presented as mean ± SD,
(n= 3), (n= 2 for compounds 12 and 14) (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this
article).
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Fig. 2. Quercetin and its derivatives decreased the deacetylation activity of SIRT6 at 50 and 200 μM concentrations. The acetylation status was evaluated by
determining the remaining levels of histone H3 acetylated on lysine 9 and normalized to total H3 histone. (A) Images of immunoblot analysis. (B) Relative SIRT6
H3K9Ac deacetylation activity. Values are expressed as mean ± standard error of mean (SEM) of three independent experiment (*p values< 0.05 vs. control, **p
values< 0.01 vs. control; one way-ANOVA with Bonﬀeroni and Dunnett post hoc test). (C) Structure of quercetin, compound 25 and 3.
Fig. 3. Inhibition of SIRT6 deacetylation activity by compounds 25 and 3. (A) Dose response curves for inhibition with diﬀerent compounds concentrations. The IC50
values of compounds 25 and 3 were 130 μM (113–165 μM, 95% conﬁdence interval) and 55 μM (50–79 μM, 95% conﬁdence interval), respectively. The data is
presented as mean ± SD, (n=3). Lineweaver-Burk plots for compounds 25 and 3 with increasing concentration of (B) peptide substrate (C) NAD+ cofactor. The
data is presented as mean ± SEM, (n= 3).
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3.2. In vitro studies for SIRT1–3
To investigate the selectivity of the most potent compounds 25 and
3 with respect to other SIRTs, ﬂuorogenic in vitro assays were con-
structed against SIRT1–3 at a concentration of 50 μM (Supplementary
Table S2). Compound 25 displayed 20–30% inhibition against SIRT1–3
and SIRT6, whereas compound 3 showed 80% and 60% inhibition
against SIRT2 and SIRT1, respectively (Fig. 4A). The dose-response
analysis for compound 3 against SIRT2 showed an IC50 value of 14 μM
(Fig. 4B). Interestingly, compound 3 displayed 72% inhibition towards
SIRT2, whereas known SIRT inhibitors Ex-527 and Suramin showed
46% and 29% inhibition, respectively, at a concentration of 10 μM
(Supplementary Table S3).
3.3. Molecular docking study
The most potent inhibitors, compounds 25 and 3, were docked to
SIRT6. All four isomers of compound 25 docked to the inhibitor binding
site locating close to NAM moiety binding site. The isomer with best
glide docking score (-12.862) formed interactions with Asn2, Phe80,
Thr83, Phe84, Val113, Asp114, and His131 (Fig. 5A). His131 is the
catalytically active histidine, that interacts with cofactor NAD+ during
deacetylation reaction. Thus, by interacting with His131 compound 25
might disturb the reaction between NAD+ and His131. Compound 3
did not dock as well to this binding site; the lipophilic 2-chloro-1,4-
naphthoquinone moiety directed into the solvent outside of the binding
site. Two-dimensional interaction ﬁgures of these compounds at this
binding site are presented in Supplementary Fig. S2.
At the substrate binding site compound 3 formed interactions with
Trp186, Glu187, and Asp188, and interacted also with Phe62 (Fig. 5B).
Only one isomer of compound 25 had a pose at the substrate binding
site, where it formed interactions with Asp185, Glu187, and Arg218. At
the same time, it formed interactions also with Asn2, Asp12, Phe62,
Arg63, Val113, and Asp114. Two-dimensional interactions of these
compounds at the substrate binding site are presented in Supplemen-
tary Fig. S3.
Compound 25 isomers and compound 3 were docked also to SIRT2
at the binding site of co-crystallized ligand SirReal2, but were placed
slightly diﬀerently than SirReal2 did (Supplementary Fig. 4A). Some
isomers of compound 25 had similar interactions as SirReal2, which
had three π-π staking interactions to Phe131, Phe190 and Phe234.
Compound 3 did not form interactions similar to SirReal2. Two-di-
mensional interactions of SirReal2, compound 25, and compound 3 are
presented in Supplementary Figs. 4B-D.
Fig. 4. (A) Compound 3 was more potent in-
hibitor towards SIRT1-3 than SIRT6. Sirtuin
screen was constructed using ﬂuorogenic based
assay with recombinant enzymes at 50 μM
concentration of compounds. (B) Dose re-
sponse curve for SIRT2 inhibition with dif-
ferent concentrators of compound 3 that pro-
vides the IC50 value of 14μM (13–16 μM, 95%
conﬁdence interval). The data is presented as
mean ± SD, (n=3).
Fig. 5. Docking sites near to the binding site of NAM moiety of NAD+ (a) and near to substrate binding site (b). NAD+ binding site is close the two docking sites. (A)
Interactions of compound 25 at the binding site near to NAM moiety binding site. Black dashes indicate hydrogen bonding and magenta dashes indicate π-π stacking.
(B) Interactions of compound 3 at substrate binding site.
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4. Discussion
Compared to SIRT1–3, only a few SIRT6 regulators have been de-
scribed in the literature to date [17,34,35,39–41]. The lack of SIRT6
regulators retards the development of clinically relevant compounds.
Thus, there is an increasing need for identifying various scaﬀolds to be
used as starting points for developing potent and selective SIRT6 in-
hibitors and activators. We demonstrated in a recent study that dif-
ferent classes of ﬂavonoids either inhibit or activate the deacetylation
activity of SIRT6. Moreover, the eﬀect depends on the ﬂavonoid sub-
class; that is, catechins showed inhibition, whereas anthocyanidins
showed activation [17]. In addition, some of the ﬂavonones and ﬂa-
vonols, including kaempferol and quercetin, show a dual role against
SIRT6; that is, they both inhibit and activate SIRT6 depending on the
substrate concentration [17].
In the present study, the SIRT6 activity of kaempferol and quercetin
was tested using two diﬀerent assays with diﬀerent substrates. Both
assays showed that quercetin and some quercetin derivatives inhibited
SIRT6. Kaempferol was a weak activator according to the im-
munoblotting assay but a activator according to the ﬂuorogenic-based
assay. In the ﬂuorogenic-based assay, the substrate was an H3 peptide
sequence [Ac-RYQK (Ac)-AMC] that mimics the biological deacetyla-
tion site of histone 3 lysine 56 (H3K56) with Nε-acetylated lysine.
However, the substrate of the immunoblotting assay consisted of the
core histone including the full-length H3 peptide. The inhibition or
activation results of SIRT6 may be dependent on the substrate used.
In the deacetylation reaction, SIRTs transfer the acetyl group from
the lysine residue of the substrate to the adenosine diphosphate (ADP)
ribose moiety of NAD+. This process is followed by the release of NAM,
O-acetyl-ADP ribose, and deacetylated substrates. The NAM moiety of
NAD+ and the acetyl group of the substrate lysine are placed facing
towards each other and are adjacent to catalytic histidine residue in-
volved in the reaction. Our experiments (Fig. 3) show that compound
25 displayed a competitive behavior with NAD+, suggesting that
compound 25 could prevent the binding of NAD+ or NAM and subse-
quently prevent the reaction. On the contrary, compound 3 competed
with the peptide substrate, indicating that compound 3 would bind
onto the binding site of substrate.
A mechanistic explanation is not possible based on these simpliﬁed
models, but the results provide information about possible compound
binding sites. In addition, inhibitor binding can rarely be described with
one model. However, a common model of enzyme inhibition kinetics is
a mixed inhibition type that represents a combination of competitive
and noncompetitive inhibition [42]. Our molecular docking studies
support these ﬁndings. The docking results suggest that compound 25
preferred the binding site of NAM moiety, where it formed interaction
with catalytic histidine (His131). This result may indicate that com-
pound 25 can compete with NAD+ by preventing NAD+ from inter-
acting with catalytic histidine. In contrast, compound 3 preferred to
dock onto the acetylated substrate binding site and formed interactions
with Trp186, Glu187 and Asp188 locating in β6/α6 loop. The im-
portance of this loop region for substrate binding has been previously
discussed [17,43,44]. Both compounds 25 and 3 were also docked onto
the binding site of SirReal2 in SIRT2, but they were situated slightly
diﬀerently compared with SirReal2. Compound 25 had an interaction
with Phe190 similar to that of SirReal2. Additionally, compound 25
formed fewer hydrogen bonds at SIRT2 than at SIRT6.
Quercetin and related ﬂavonoids are broad-spectrum inhibitors of
many protein kinases and cyclooxygenase [45,46], but understanding
the mechanism of action of quercetin requires the description of its
entire target space. In previous studies, quercetin derivatives (21
compounds, including all agents studied here) were tested in vitro to
evaluate radical scavenging activity [47]. The most potent compounds
of this study, compounds 25 and 3, decreased SERCA activity, which
may also contribute to anticancer activity [48–50]. The compound with
the most pro-oxidant properties, compound 3, exerted an antitumor
eﬀect that was conﬁrmed in colorectal cancer cell lines HCT-116 and
HT-29 [51].
Quercetin may be a promising compound for the management of
type 2 diabetes. It has been observed that aldose reductase (ALR2) in-
hibitors play a signiﬁcant role against diabetic complications [52].
Thus, quercetin derivatives were analyzed for their ALR2 inhibitory
eﬀects [10], where compound 3 exhibited the highest biological ac-
tivity. In the studies of Milackova et al. [12] and Soltesova-Prnova et al.
[13], ALR2 inhibition by compounds 3 and 2 was examined in more
detail. The anti-inﬂammatory eﬀects were indicated in the microglial
cell line (BV-2) as well as in vivo for compound 2 and compound 3,
respectively [53,54]. Taken together, these studies indicate that poly-
phenols are multi-targeting compounds that aﬀect proteins associated
with cancer and diabetes. Polyphenols may have broad therapeutic
implications for cancer and other age-related diseases.
5. Conclusions
Polyphenols are known sirtuin modulators. Several polyphenols
were screened in vitro to detect new modulators for SIRT6. Two quer-
cetin derivatives, diquercetin and 2-chloro-1,4-naphthoquinone-quer-
cetin, showed inhibition towards the deacetylation activity of SIRT6.
The docking results of compounds 25 and 3 support the in vitro results.
The most potent compounds were also tested for other SIRTs and were
found to be even more potent towards SIRT2 but not towards SIRT1.
These new compounds can be used for developing more potent SIRT
inhibitors. Future studies are required to understand the eﬀects of
polyphenols in SIRT-mediated mechanisms of various abnormal cellular
and biological functions. Overall, co-targeting of SIRT6 with other
proteins/oncogenes by dietary polyphenols opens an eﬃcient, logical,
and alternative approach against many age-related diseases.
Conﬂict of interest
The authors declare that there are no conﬂicts of interest.
Acknowledgements
We thank Sari Ukkonen for her skillful assistance. The computa-
tional capacity and licenses support provided by CSC-IT Center for
Science, Finland, is acknowledged. The research was done in colla-
boration network of COST Action CM1407. M.R-R. was supported by
Academy of Finland (grant no. 269341), Finnish Cultural Foundation
and Maud Kuistila Memorial Foundation. V.H. was supported by the
Slovak National grants VEGA2/0111/16. A.H. was supported by
the<GS3>National Research, Development and Innovation Oﬃce,
Hungary< /GS4> (NKFIH;<GN3>K119770< /GN4>). Ministry
of Human Capacities, Hungary grant 20391-3/2018/FEKUSTRAT is
acknowledged.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.biopha.2019.01.035.
References
[1] Y. Kanﬁ, S. Naiman, G. Amir, V. Peshti, G. Zinman, L. Nahum, Z. Bar-Joseph,
H.Y. Cohen, The sirtuin SIRT6 regulates lifespan in male mice, Nature 483 (7388)
(2012) 218–221, https://doi.org/10.1038/nature10815.
[2] S. Kaluski, M. Portiollo, A. Besnard, D. Stein, M. Einav, L. Zhong, U. Ueberham,
T. Arendt, R. Mostoslavsky, A. Sahay, D. Toiber, Neuroprotective functions for the
histone deacetylase SIRT6, Cell Rep. 18 (13) (2017) 3052–3062, https://doi.org/
10.1016/j.celrep.2017.03.008.
[3] L. Tasselli, W. Zheng, K.F. Chua, SIRT6: novel mechanisms and links to aging and
disease, Trends Endocrinol. Metab. 28 (3) (2017) 168–185, https://doi.org/10.
1016/j.tem.2016.10.002.
[4] C. Sebastian, B.M.M. Zwaans, D.M. Silberman, M. Gymrek, A. Goren, L. Zhong,
V. Heger et al. Biomedicine & Pharmacotherapy 111 (2019) 1326–1333
1331
O. Ram, J. Truelove, A.R. Guimaraes, D. Toiber, C. Cosentino, J.K. Greenson,
A.I. MacDonald, L. McGlynn, F. Maxwell, J. Edwards, S. Giacosa, E. Guccione,
R. Weissleder, B.E. Bernstein, A. Regev, P.G. Shiels, D.B. Lombard, R. Mostoslavsky,
The histone deacetylase SIRT6 is a novel tumor suppressor that controls cancer
metabolism, Cell 151 (6) (2012) 1185–1199, https://doi.org/10.1016/j.cell.2012.
10.047.
[5] B. Lerrer, A.A. Gertler, H.Y. Cohen, The complex role of SIRT6 in carcinogenesis,
Carcinogenesis 37 (2) (2016) 108–118, https://doi.org/10.1093/carcin/bgv167.
[6] V. Desantis, A. Lamanuzzi, A. Vacca, The role of SIRT6 in tumors, Haematologica
103 (1) (2018) 1–4, https://doi.org/10.3324/haematol.2017.182675.
[7] M. Imran, H. Khan, M. Shah, R. Khan, F. Khan, Chemical composition and anti-
oxidant activity of certain Morus species, J. Zhejiang Univ. Sci. B 11 (12) (2010)
973–980, https://doi.org/10.1631/jzus.B1000173.
[8] I.I. da S. Junior, H. de M. Barbosa, D.C.R. Carvalho, R. de A. Barros,
F.P. Albuquerque, D.H.A. da Silva, G.R. Souza, N.A.C. Souza, L.A. Rolim,
F.M.M. Silva, G.I.B.P. Duarte, J.R.G. da S. Almeida, F.M. de O Junior, D.A. Gomes,
E.C. Lira, Brazilian Morus nigra attenuated hyperglycemia, dyslipidemia, and
prooxidant status in alloxan-induced diabetic rats, Sci. World J. 2017 (2017)
5275813, , https://doi.org/10.1155/2017/5275813.
[9] I. Turan, S. Demir, K. Kilinc, N.A. Burnaz, S.O. Yaman, K. Akbulut, A. Mentese,
Y. Aliyazicioglu, O. Deger, Antiproliferative and apoptotic eﬀect of Morus nigra
extract on human prostate cancer cells, Saudi Pharm. J. 25 (2) (2017) 241–248,
https://doi.org/10.1016/j.jsps.2016.06.002.
[10] M. Veverka, J. Gallovic, E. Svajdlenka, E. Veverkova, N. Pronayova, I. Milackova,
M. Stefek, Novel quercetin derivatives: synthesis and screening for anti-oxidant
activity and aldose reductase inhibition, Chem. Pap. 67 (1) (2013) 76–83, https://
doi.org/10.2478/s11696-012-0240-5.
[11] P. Zizkova, M. Stefek, L. Rackova, M. Prnova, L. Horakova, Novel quercetin deri-
vatives: from redox properties to promising treatment of oxidative stress related
diseases, Chem. Biol. Interact. 265 (2017) 36–46, https://doi.org/10.1016/j.cbi.
2017.01.019.
[12] I. Milackova, M. Soltesova Prnova, M. Majekova, R. Sotnikova, M. Stasko,
L. Kovacikova, S. Banerjee, M. Veverka, M. Stefek, 2-Chloro-1,4-naphthoquinone
derivative of quercetin as an inhibitor of aldose reductase and anti inﬂammatory
agent, J. Enzyme Inhib. Med. Chem. 30 (1) (2015) 107–113, https://doi.org/10.
3109/14756366.2014.892935.
[13] M. Soltesova-Prnova, I. Milackova, M. Stefek, 3′-O-(3-Chloropivaloyl)quercetin, α-
glucosidase inhibitor with multi-targeted therapeutic potential in relation to dia-
betic complications, Chem. Pap. 70 (11) (2016) 1439–1444, https://doi.org/10.
1515/chempap-2016-0078.
[14] K.T. Howitz, K.J. Bitterman, H.Y. Cohen, D.W. Lamming, S. Lavu, J.G. Wood,
R.E. Zipkin, P. Chung, A. Kisielewski, L.-L. Zhang, B. Scherer, D.A. Sinclair, Small
molecule activators of sirtuins extend Saccharomyces cervisiae lifespan, Nature 425
(6954) (2003) 191–196, https://doi.org/10.1038/nature01960.
[15] N. Trevino-Saldana, G. Garcia-Rivas, Regulation of sirtuin-mediated protein dea-
cetylation by cardioprotective, Phytochem. Oxid. Med. Cell. Longev. 2017 (2017)
1750306, , https://doi.org/10.1155/2017/1750306.
[16] A.E. Peredo-Escarcega, V. Guarner-Lans, I. Perez-Torres, S. Ortega-Ocampo,
E. Carreon-Torres, V. Castrejon-Tellez, E. Diaz-Diaz, M.E. Rubio-Ruiz, The combi-
nation of resveratrol and quercetin attenuates metabolic syndrome in rats by
modifying the serum fatty acid composition and by upregulating SIRT 1 and SIRT 2
expression in white adipose tissue, Evid. Complement. Alternat. Med. 2015 (2015)
474032, , https://doi.org/10.1155/2015/474032.
[17] M. Rahnasto-Rilla, J. Tyni, M. Huovinen, E. Jarho, T. Kulikowicz, S. Ravichandran,
V.A. Bohr, L. Ferucci, M. Lahtela-Kakkonen, R. Moaddel, Natural polyphenols as
sirtuin 6 modulators, Sci. Rep. 8 (2018) 4163, https://doi.org/10.1038/s41598-
018-22388-5.
[18] Y.T. Lin, J.S. Yang, H.J. Lin, T.W. Tan, N.Y. Tang, J.H. Chaing, Y.H. Chang, H.F. Lu,
J.G. Chung, Baicalein induces apoptosis in SCC-4 human tongue cancer cells via a
Ca2+-dependent mitochondrial pathway, In Vivo (Brooklyn) 21 (6) (2007)
1053–1058.
[19] O.A. Ogunbayo, R.M. Harris, R.H. Waring, C.J. Kirk, F. Michelangeli, Inhibition of
the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase by ﬂavonoids: a quantitative
structure-activity relationship study, IUBMB Life 60 (12) (2008) 853–858, https://
doi.org/10.1002/iub.132.
[20] L. Horakova, M.K. Strosova, C.M. Spickett, D. Blaskovic, Impairment of calcium
ATPases by high glucose and potential pharmacological protection, Free Radic. Res.
47 (Suppl. 1) (2013) 81–92, https://doi.org/10.3109/10715762.2013.807923.
[21] X. Xiong, G. Wang, R. Tao, P. Wu, T. Kono, K. Li, W.-X. Ding, X. Tong, S.A. Tersey,
R.A. Harris, R.G. Mirmira, C. Evans-Molina, X. Charlie Dong, Sirtuin 6 regulates
glucose-stimulated insulin secretion in mouse pancreatic beta cells, Diabetologia 59
(1) (2016) 151–160, https://doi.org/10.1007/s00125-015-3778-2.
[22] M. Danihelova, M. Veverka, E. Sturdik, S. Jantova, Antioxidant action and cyto-
toxicity on HeLa and NIH-3T3 cells of new quercetin derivatives, Interdiscip.
Toxicol. 6 (4) (2014) 209–216, https://doi.org/10.2478/intox-2013-0031.
[23] J. Viskupicova, M. Majekova, L. Horakova, Inhibition of the sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA1) by rutin derivatives, J. Muscle Res. Cell. Motil.
36 (2) (2015) 183–194, https://doi.org/10.1007/s10974-014-9402-0.
[24] J. Viskupicova, M.K. Strosova, P. Zizkova, M. Majekova, L. Horakova, Rutin sti-
mulates sarcoplasmic reticulum Ca2+-ATPase activity (SERCA1) and protects
SERCA1 from peroxynitrite mediated injury, Mol. Cell. Biochem. 402 (1–2) (2015)
51–62, https://doi.org/10.1007/s11010-014-2313-y.
[25] V. Heger, J. Viskupicova, Z. Zooﬁshan, A. Hunyadi, L. Horakova, Sarco/en-
doplasmic Ca2+ -ATPase (SERCA) and pancreatic beta cells modiﬁed by prenylated
phenolic compounds from Morus nigra, Biomed. Biopharm. Res. 14 (2) (2017) 282,
https://doi.org/10.19277/bbr.14.2.168.
[26] A. Raza, X. Xu, L. Xia, C. Xia, J. Tang, Z. Ouyang, Quercetin-iron complex: synthesis,
characterization, antioxidant, DNA binding, DNA cleavage, and antibacterial ac-
tivity studies, J. Fluoresc. 26 (6) (2016) 2023–2031, https://doi.org/10.1007/
s10895-016-1896-y.
[27] J. Viskupicova, M. Danihelova, M. Ondrejovic, T. Liptaj, E. Sturdik, Lipophilic rutin
derivatives for antioxidant protection of oil-based foods, Food Chem. 123 (1)
(2010) 45–50, https://doi.org/10.1016/j.foodchem.2010.03.125.
[28] J.Y. Kim, W.S. Lee, Y.S. Kim, M.J. Curtis-Long, B.W. Lee, Y.B. Ryu, K.H. Park,
Isolation of cholinesterase-inhibiting ﬂavonoids from Morus Ihou, J. Agric. Food
Chem. 59 (9) (2011) 4589–4596, https://doi.org/10.1021/jf200423g.
[29] S.H. Jeong, Y.B. Ryu, M.J. Curtis-Long, H.W. Ryu, Y.S. Baek, J.E. Kang, W.S. Lee,
K.H. Park, Tyrosinase inhibitory polyphenols from roots of Morus Ihou, J. Agric.
Food Chem. 57 (4) (2009) 1195–1203, https://doi.org/10.1021/jf8033286.
[30] H.J. Lee, D.H. Lyu, U. Koo, S.-J. Lee, S.S. Hong, K. Kim, K.H. Kim, D. Lee, W. Mar,
Inhibitory eﬀect of 2-arylbenzofurans from the Mori Cortex Radicis (Moraceae) on
oxygen glucose deprivation (OGD)-induced cell death of SH-SY5Y cells, Arch.
Pharm. Res. 34 (8) (2011) 1373–1380, https://doi.org/10.1007/s12272-011-
0818-4.
[31] G.D.W.F. Kapche, C.D. Fozing, J.H. Donfack, G.W. Fotso, D. Amadou, A.N. Tchana,
M. Bezabih, P.F. Moundipa, B.T. Ngadjui, B.M. Abegaz, Prenylated arylbenzofuran
derivatives from Morus mesozygia with antioxidant activity, Phytochemistry. 70 (2)
(2009) 216–221, https://doi.org/10.1016/j.phytochem.2008.12.014.
[32] M. Algso, A. Kivrak, M. Konus, C. Yilmaz, A. Kurt-Kizildoğan, Synthesis and bio-
logical evaluation of novel benzothiophene derivatives, J. Chem. Sci. Bangalore
(Bangalore) 130 (9) (2018) 119, https://doi.org/10.1007/s12039-018-1523-3.
[33] M. Algso, A. Kivrak, New strategy for the synthesis of 3-ethynyl-2-(thiophen-2-yl)
benzo[b]thiophene derivatives, Chem. Papers (2018), https://doi.org/10.1007/
s11696-018-0640-2.
[34] P. Kokkonen, M. Rahnasto-Rilla, P. Mellini, E. Jarho, M. Lahtela-Kakkonen,
T. Kokkola, Studying SIRT6 regulation using H3K56 based substrate and small
molecules, Eur. J. Pharm. Sci. 63 (2014) 71–76, https://doi.org/10.1016/j.ejps.
2014.06.015.
[35] M.K. Rahnasto-Rilla, P. McLoughlin, T. Kulikowicz, M. Doyle, V.A. Bohr,
M. Lahtela-Kakkonen, L. Ferrucci, M. Hayes, R. Moaddel, The Identiﬁcation of a
SIRT6 Activator from Brown Algae Fucus distichus, Mar. Drugs 15 (6) (2017) 190,
https://doi.org/10.3390/md15060190.
[36] Small-Molecule Drug Discovery Suite 2017-4, Schrödinger, LLC, New York, NY,
2017.
[37] H. Jiang, S. Khan, Y. Wang, G. Charron, B. He, C. Sebastian, J. Du, R. Kim, E. Ge,
R. Mostoslavsky, H.C. Hang, Q. Hao, H. Lin, Sirt6 regulates TNFα secretion via
hydrolysis of long chain fatty acyl lysine, Nature 496 (7443) (2013) 110–113,
https://doi.org/10.1038/nature12038.
[38] T. Rumpf, M. Schiedel, B. Karaman, C. Roessler, B.J. North, A. Lehotzky, J. Olah,
K.I. Ladwein, K. Schmidtkunz, M. Gajer, M. Pannek, C. Steegborn, D.A. Sinclair,
S. Gerhardt, J. Ovadi, M. Schutkowski, W. Sippl, O. Einsle, M. Jung, Selective Sirt2
inhibition by ligand-induced rearrangement of the active site, Nat. Commun. 6
(2015) 6263, https://doi.org/10.1038/ncomms7263.
[39] M. Yasuda, D.R. Wilson, S.D. Fugmann, R. Moaddel, Synthesis and characterization
of SIRT6 protein coated magnetic beads: identiﬁcation of a novel inhibitor of SIRT6
deacetylase from medicinal plant extracts, Anal. Chem. 83 (19) (2011) 7400–7407,
https://doi.org/10.1021/ac201403y.
[40] P. Kokkonen, M. Rahnasto-Rilla, P.H. Kiviranta, T. Huhtiniemi, T. Laitinen, A. Poso,
E. Jarho, M. Lahtela-Kakkonen, Peptides and pseudopeptides as SIRT6 deacetyla-
tion inhibitors, ACS Med. Chem. Lett. 3 (12) (2012) 969–974, https://doi.org/10.
1021/ml300139n.
[41] G. Sociali, L. Galeno, M.D. Parenti, A. Grozio, I. Bauer, M. Passalacqua, S. Boero,
A. Donadini, E. Millo, M. Bellotti, L. Sturla, P. Damonte, A. Puddu, C. Ferroni,
G. Varchi, C. Franceschi, A. Ballestrero, A. Poggi, S. Bruzzone, A. Nencioni, A. Del
Rio, Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics,
Eur. J. Med. Chem. 102 (2015) 530–539, https://doi.org/10.1016/j.ejmech.2015.
08.024.
[42] H.I. Segel, Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and
Steady-State Enzyme Systems, Wiley-Interscience, New York, USA, 2007.
[43] P.W. Pan, J.L. Feldman, M.K. Devries, A. Dong, A.M. Edwards, J.M. Denu, Structure
and biochemical functions of SIRT6, J. Biol. Chem. 286 (16) (2011) 14575–14587,
https://doi.org/10.1074/jbc.M111.218990.
[44] H. Yuan, R. Marmorstein, Structural basis for sirtuin activity and inhibition, J. Biol.
Chem. 287 (51) (2012) 42428–42435, https://doi.org/10.1074/jbc.R112.372300.
[45] V. Garcia-Mediavilla, I. Crespo, P.S. Collado, A. Esteller, S. Sanchez-Campos,
M.J. Tunon, J. Gonzalez-Gallego, The anti-inﬂammatory ﬂavones quercetin and
kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2
and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway
in Chang Liver cells, Eur. J. Pharmacol. 557 (2–3) (2007) 221–229, https://doi.org/
10.1016/j.ejphar.2006.11.014.
[46] G.L. Russo, M. Russo, C. Spagnuolo, I. Tedesco, S. Bilotto, R. Iannitti, R. Palumbo,
Quercetin: a pleiotropic kinase inhibitor against cancer, in: V. Zappia, S. Panico,
G. Russo, A. Budillon, F. Della Ragione (Eds.), Advances in Nutrition and Cancer,
Springer, Berlin, Heidelberg, 2014, pp. 185–205, , https://doi.org/10.1007/978-3-
642-38007-5_11.
[47] I. Milackova, L. Kovacikova, M. Veverka, J. Gallovic, M. Stefek, Screening for an-
tiradical eﬃciency of 21 semi-synthetic derivatives of quercetin in a DPPH assay,
Interdiscip. Toxicol. 6 (1) (2013) 13–17, https://doi.org/10.2478/intox-2013-
0003.
[48] D. Blaskovic, F. Drzik, J. Viskupicova, M. Veverka, L. Horakova, Eﬀects of novel
quercetin derivatives on sarco/endoplasmic reticulum Ca2+-ATPase activity, Free
Radic. Biol. Med. 53 (Suppl. 1) (2012) S92–S93, https://doi.org/10.1016/j.
V. Heger et al. Biomedicine & Pharmacotherapy 111 (2019) 1326–1333
1332
freeradbiomed.2012.08.193.
[49] D. Blaskovic, P. Zizkova, F. Drzik, J. Viskupicova, M. Veverka, L. Horakova,
Modulation of rabbit muscle sarcoplasmic reticulum Ca2+-ATPase activity by novel
quercetin derivatives, Interdiscip. Toxicol. 6 (1) (2013) 3–8, https://doi.org/10.
2478/intox-2013-0001.
[50] P. Zizkova, D. Blaskovic, M. Majekova, L. Svorc, L. Rackova, L. Ratkovska,
M. Veverka, L. Horakova, Novel quercetin derivatives in treatment of peroxynitrite-
oxidized SERCA1, Mol. Cell. Biochem. 386 (1–2) (2014) 1–14, https://doi.org/10.
1007/s11010-013-1839-8.
[51] S. Enayat, M. Seyma Ceyhan, B. Taskoparan, M. Stefek, S. Banerjee, CHNQ, a novel
2-Chloro-1,4-naphthoquinone derivative of quercetin, induces oxidative stress and
autophagy both in vitro and in vivo, Arch. Biochem. Biophys. 596 (2016) 84–98,
https://doi.org/10.1016/j.abb.2016.03.004.
[52] W.H. Tang, K.A. Martin, J. Hwa, Aldose reductase, oxidative stress, and diabetic
mellitus, Front. Pharmacol. 3 (2012) 87, https://doi.org/10.3389/fphar.2012.
00087.
[53] M. Kuniakova, N. Mrvova, V. Knezl, L. Rackova, Eﬀect of novel quercetin pivaloyl
ester on functions of adult rat microglia, Biologia 70 (5) (2015) 690–702, https://
doi.org/10.1515/biolog-2015-0082.
[54] N. Mrvova, M. Skandik, M. Kuniakova, L. Rackova, Modulation of BV-2 microglia
functions by novel quercetin pivaloyl ester, Neurochem. Int. 90 (2015) 246–254,
https://doi.org/10.1016/j.neuint.2015.09.005.
V. Heger et al. Biomedicine & Pharmacotherapy 111 (2019) 1326–1333
1333
